Immunic Appoints Jon Congleton to Board Amid Pivotal Trials and Regulatory Progress
- Immunic appointed Jon Congleton to its Board of Directors, enhancing leadership for advancing vidofludimus calcium trials.
- Congleton brings extensive experience in CNS drug development, vital for Immunic’s regulatory approval process.
- Immunic regained Nasdaq compliance with a bid price above $1.00, supporting its focus on clinical program advancement.
Immunic Strengthens Leadership Amidst Regulatory Milestones
Immunic, Inc., a late-stage biotechnology company specializing in innovative oral therapeutics for neurologic diseases, announces the appointment of Jon Congleton to its Board of Directors. This strategic addition, effective March 27, 2026, aligns with the company's mission to enhance its capabilities, especially as it advances its lead candidate, vidofludimus calcium, through pivotal trials. With nearly four decades of experience in the biopharmaceutical industry, Congleton’s expertise in drug development and commercialization—particularly in the central nervous system (CNS) sector—positions him as a valuable asset for Immunic. His work in launching Teva Pharmaceuticals' Copaxone®, which holds a prominent place in the treatment of relapsing forms of multiple sclerosis (MS), showcases his ability to steer innovative therapies from conception to market.
Congleton’s previous roles as CEO at Impel NeuroPharma and Nivalis Therapeutics, along with senior positions at Teva, have equipped him with a deep understanding of both the commercial landscape and the scientific nuances underpinning CNS therapies. Immunic's Interim Chairperson, Simona Skerjanec, expresses confidence in Congleton’s capabilities, emphasizing that his extensive experience in drug commercialization will be instrumental in guiding Immunic through the complexities of regulatory approval. The company is poised at a crucial juncture, with the forthcoming results of phase 3 clinical trials for vidofludimus calcium eagerly anticipated, given its promising therapeutic profile evidenced in earlier studies.
Vidofludimus calcium stands out in Immunic’s pipeline for its first-in-class mechanism as a nuclear receptor-related 1 (Nurr1) activator, coupled with selective inhibition of dihydroorotate dehydrogenase (DHODH). This multifaceted approach offers potential neuroprotective, anti-inflammatory, and antiviral effects, which could significantly improve treatment outcomes for MS patients. As Immunic continues to deepen its pipeline with additional programs targeting neurodegenerative and autoimmune conditions, the entry of an expert like Congleton heralds a robust step forward for the company. His enthusiasm for joining Immunic during this pivotal phase fuels optimism about the future potential of its therapies, particularly vidofludimus calcium, as an agent of change in the treatment of multiple sclerosis.
In addition to enhancing its leadership team, Immunic also confirms its regained compliance with Nasdaq’s minimum bid price requirements, marking another milestone for the company. Having achieved a bid price of $1.00 or higher for 20 consecutive business days, this compliance issue is resolved, allowing Immunic to maintain its focus on advancing its clinical programs. The anticipated top-line data from the phase 3 trials, expected by the end of 2026, represents a significant milestone for the company and its shareholders, while reaffirming Immunic's commitment to addressing unmet needs in the CNS therapeutic landscape.